The use of methotrexate in dermatology: A review

Australasian Journal of Dermatology

Volumn 53, Issue 1, 2012, Pages 1-18

  Shen, Sarah ^a   O'Brien, Tim ^a   Yap, Lei Mee ^a   Prince, H Miles ^b   McCormack, Christopher J ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

adverse reactions; mechanism of action; methotrexate; pharmacology; psoriasis; treatment guidelines

Indexed keywords

ABORTIVE AGENT; ALCOHOL; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; CEFALOTIN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPYRIDAMOLE; HOMOCYSTEINE; METHIONINE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PHENYLBUTAZONE; PHENYTOIN; PROBENECID; RETINOID; SALICYLIC ACID; SPERMIDINE; SPERMINE; SULFONAMIDE; TERATOGENIC AGENT;

ANOREXIA; ATOPIC DERMATITIS; BONE MARROW SUPPRESSION; CHRONIC URTICARIA; DERMATOMYOSITIS; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; EPSTEIN RELATED LYMPHOMA; FATIGUE; FIBROSIS; GRANULOMA ANNULARE; HEADACHE; HEPATITIS; HUMAN; HYPOALBUMINEMIA; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER CIRRHOSIS; LIVER TOXICITY; LOCALIZED SCLERODERMA; LUNG FIBROSIS; LYMPHOMATOID PAPULOSIS; MACROCYTIC ANEMIA; MALAISE; MUCOSA INFLAMMATION; MYCOSIS FUNGOIDES; NAUSEA AND VOMITING; OLIGOSPERMIA; PANCYTOPENIA; PHOTOSENSITIVITY; PITYRIASIS LICHENOIDES; PITYRIASIS RUBRA PILARIS; PNEUMONIA; PSORIASIS; PSORIATIC ARTHRITIS; PURINE SYNTHESIS; PUVA; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SKIN LUPUS ERYTHEMATOSUS; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; VASCULITIS;

EID: 84856953675     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2011.00839.x     Document Type: Review

References (208)

1. Gubner RS,. Introduction of antifolics in psoriasis. A twenty-five year retrospect of antineoplastic agents in nonmalignant disease. Cutis 1979; 23: 425-8. (Pubitemid 9154057)
2. Weinstein GD, Frost P,. Methotrexate for psoriasis. A new therapeutic schedule. Arch. Dermatol. 1971; 103: 33-8.
3. Weinstein GD, Goldfaden G, Frost P,. Methotrexate. Mechanism of action on DNA synthesis in psoriasis. Arch. Dermatol. 1971; 104: 236-43.
4. Mainman H, McClaren E, Heycock C, et al,. When should we use parenteral methotrexate? Clin. Rheumatol. 2010; 29: 1093-8.
5. Hamilton RA, Kremer JM,. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with RA. Br. J. Rheumatol. 1997; 36: 86-90.
6. Wegrzyn J, Adeleine P, Miossec P,. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2004; 63: 1232-4. (Pubitemid 39273499)
7. Godfrey C, Sweeney K, Miller K, et al,. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br. J. Clin. Pharmacol. 1998; 46: 369-76.
8. Braun J, Kästner P, Flaxenberg P, et al,. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008; 58: 73-81.
9. Olsen EA,. The pharmacology of methotrexate. J. Am. Acad. Dermatol. 1991; 25: 306-18.
10. Swierkot J, Szechiński J,. Methotrexate in rheumatoid arthritis. Pharmacol. Rep. 2006; 58: 473-92. (Pubitemid 44383273)
11. Oguey D, Kölliker F, Gerber NJ, et al,. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1992; 35: 611-14.
12. Bleyer WA,. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978; 41: 36-51. (Pubitemid 8286409)
13. Chan ES, Cronstein BN,. Methotrexate-how does it really work? Nat. Rev. Rheumatol. 2010; 6: 175-8.
14. Nesher G, Moore TL, Dorner RW,. In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine. Ann. Rheum. Dis. 1991; 50: 637-41.
15. Cronstein BN, Naime D, Ostad E,. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 1993; 92: 2675-82. (Pubitemid 24006532)
16. Montesinos MC, Desai A, Cronstein BN,. Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res. Ther. 2006; 8: R53.
17. Haskõ G, Cronstein BN,. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004; 25: 33-9. (Pubitemid 38032805)
18. Andersson SE, Johansson LH, Lexmüller K, et al,. Anti-arthritic effect of methotrexate: is it really mediated by adenosine? Eur. J. Pharm. Sci. 2000; 9: 333-43. (Pubitemid 30069524)
19. Phillips DC, Woollard KJ, Griffiths HR,. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br. J. Pharmacol. 2003; 138: 501-11. (Pubitemid 36269490)
20. al-Awadhi A, Dale P, McKendry RJ,. Pancytopenia associated with low dose methotrexate therapy. A regional survey. J. Rheumatol. 1993; 20: 1121-5. (Pubitemid 23278160)
21. Wollina U, Ständer K, Barta U,. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis-short- and long-term toxicity in 104 patients. Clin. Rheumatol. 2001; 20: 406-10. (Pubitemid 33130475)
22. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, et al,. Methotrexate revisited: effects of long-term treatment in psoriasis. Br. J. Dermatol. 1994; 130: 204-10. (Pubitemid 24204616)
23. Lim AY, Gaffney K, Scott DG,. Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford) 2005; 44: 1051-5. (Pubitemid 41487182)
24. Duhra P,. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J. Am. Acad. Dermatol. 1993; 28: 466-9. (Pubitemid 23075264)
25. Nyfors A,. Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol. Microbiol. Scand. A 1977; 85: 511-18. (Pubitemid 8149758)
26. Zachariae H, Søgaard H, Heickendorff L,. Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies-a further 10-year follow-up. Dermatology 1996; 192: 343-6.
27. Auerbach R,. Psoriasis symposium. Methotrexate. Semin. Dermatol. 1992; 11: 23-9.
28. Kremer JM, Alarcõn GS, Lightfoot RW, et al,. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994; 37: 316-28. (Pubitemid 24093622)
29. Whiting-O'Keefe QE, Fye KH, Sack KD,. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am. J. Med. 1991; 90: 711-16.
30. Langman G, Hall PM, Todd G,. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J. Gastroenterol. Hepatol. 2001; 16: 1395-401. (Pubitemid 34107409)
31. Rosenberg P, Urwitz H, Johannesson A, et al,. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J. Hepatol. 2007; 46: 1111-18. (Pubitemid 46669734)
32. Roenigk HH, Auerbach R, Maibach HI, et al,. Methotrexate in psoriasis: revised guidelines. J. Am. Acad. Dermatol. 1988; 19: 145-56.
33. Berends MA, van Oijen MG, Snoek J, et al,. Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch. Dermatol. 2007; 143: 1515-19. (Pubitemid 350277766)
34. Robinson JK, Baughman RD, Auerbach R, et al,. Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals. Arch. Dermatol. 1980; 116: 413-15. (Pubitemid 10147457)
35. Themido R, Loureiro M, Pecegueiro M, et al,. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm. Venereol. 1992; 72: 361-4.
36. Zachariae H, Heickendorff L, Søgaard H,. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br. J. Dermatol. 2001; 144: 100-3. (Pubitemid 32154599)
37. Malatjalian DA, Ross JB, Williams CN, et al,. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can. J. Gastroenterol. 1996; 10: 369-75. (Pubitemid 26364819)
38. Stern RS, Laird N,. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 1994; 73: 2759-64. (Pubitemid 24166263)
39. Zumtobel U, Schwarze HP, Favre M, et al,. Widespread cutaneous carcinomas associated with human papillomaviruses 5, 14 and 20 after introduction of methotrexate in two long-term PUVA-treated patients. Dermatology 2001; 202: 127-30. (Pubitemid 32337163)
40. Maruani A, Wierzbicka E, Machet MC, et al,. Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. J. Am. Acad. Dermatol. 2007; 57: S69-71. (Pubitemid 47552632)
41. Georgescu L, Quinn GC, Schwartzman S, et al,. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin. Arthritis Rheum. 1997; 26: 794-804. (Pubitemid 27274443)
42. Williams CA, Bloch DA, Sibley J, et al,. Lymphoma and luekemia in rheumatoid arthritis: are they associated with azathioprine, cyclophosphamide, or methotrexate? J. Clin. Rheumatol. 1996; 2: 64-72.
43. Shiroky JB, Frost A, Skelton JD, et al,. Complications of immunosuppression associated with weekly low dose methotrexate. J. Rheumatol. 1991; 18: 1172-5.
44. Viraben R, Brousse P, Lamant L,. Reversible cutaneous lymphoma occurring during methotrexate therapy. Br. J. Dermatol. 1996; 135: 116-18. (Pubitemid 26225129)
45. Kamel OW, van de Rijn M, Weiss LM, et al,. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N. Engl. J. Med. 1993; 328: 1317-21. (Pubitemid 23131374)
46. Tournadre A, D'Incan M, Dubost JJ, et al,. Cutaneous lymphoma associated with Epstein-Barr virus infection in 2 patients treated with methotrexate. Mayo Clin. Proc. 2001; 76: 845-8. (Pubitemid 32729486)
47. Ellman MH, Hurwitz H, Thomas C, et al,. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J. Rheumatol. 1991; 18: 1741-3.
48. Usman AR, Yunus MB,. Non-Hodgkin's lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate. J. Rheumatol. 1996; 23: 1095-7. (Pubitemid 26196104)
49. Mariette X, Cazals-Hatem D, Warszawki J, et al,. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99: 3909-15. (Pubitemid 35332027)
50. Baird RD, van Zyl-Smit RN, Dilke T, et al,. Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. Br. J. Haematol. 2002; 118: 567-8. (Pubitemid 34994664)
51. Bachman TR, Sawitzke AD, Perkins SL, et al,. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum. 1996; 39: 325-9. (Pubitemid 26065275)
52. Paul C, Le Tourneau A, Cayuela JM, et al,. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch. Dermatol. 1997; 133: 867-71. (Pubitemid 27337547)
53. Chai C, White WL, Shea CR, et al,. Epstein Barr virus-associated lymphoproliferative-disorders primarily involving the skin. J. Cutan. Pathol. 1999; 26: 242-7. (Pubitemid 29296630)
54. Hirose Y, Masaki Y, Okada J, et al,. Epstein-Barr virus-associated B-cell type non-Hodgkin's lymphoma with concurrent p53 protein expression in a rheumatoid arthritis patient treated with methotrexate. Int. J. Hematol. 2002; 75: 412-15. (Pubitemid 43020300)
55. Airio A, Pukkala E, Isomäki H,. Elevated cancer incidence in patients with dermatomyositis: a population based study. J. Rheumatol. 1995; 22: 1300-3.
56. Moder KG, Tefferi A, Cohen MD, et al,. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am. J. Med. 1995; 99: 276-81.
57. Buchbinder R, Barber M, Heuzenroeder L, et al,. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008; 59: 794-9. (Pubitemid 351847561)
58. Lloyd ME, Carr M, McElhatton P, et al,. The effects of methotrexate on pregnancy, fertility and lactation. QJM 1999; 92: 551-63. (Pubitemid 29501961)
59. Temprano KK, Bandlamudi R, Moore TL,. Antirheumatic drugs in pregnancy and lactation. Semin. Arthritis Rheum. 2005; 35: 112-21. (Pubitemid 41356587)
60. Morris LF, Harrod MJ, Menter MA, et al,. Methotrexate and reproduction in men: case report and recommendations. J. Am. Acad. Dermatol. 1993; 29: 913-16. (Pubitemid 23335298)
61. Binymin K, Cooper RG,. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 341-2. (Pubitemid 32266354)
62. Gwak GY, Koh KC, Kim HY,. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin. Exp. Rheumatol. 2007; 25: 888-9. (Pubitemid 351166443)
63. Maurer TA, Zackheim HS, Tuffanelli L, et al,. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J. Am. Acad. Dermatol. 1994; 31: 372-5. (Pubitemid 24249269)
64. Phillips TJ, Jones DH, Baker H,. Pulmonary complications following methotrexate therapy. J. Am. Acad. Dermatol. 1987; 16: 373-5. (Pubitemid 17013732)
65. Kalantzis A, Marshman Z, Falconer DT, et al,. Oral effects of low-dose methotrexate treatment. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2005; 100: 52-62. (Pubitemid 40813391)
66. Pearce HP, Wilson BB,. Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J. Am. Acad. Dermatol. 1996; 35: 835-8. (Pubitemid 26389450)
67. Lawrence CM, Dahl MG,. Two patterns of skin ulceration induced by methotrexate in patients with psoriasis. J. Am. Acad. Dermatol. 1984; 11: 1059-65. (Pubitemid 15210484)
68. Kazlow DW, Federgrun D, Kurtin S, et al,. Cutaneous ulceration caused by methotrexate. J. Am. Acad. Dermatol. 2003; 49: S197-8. (Pubitemid 36951244)
69. Dierkes J, Westphal S,. Effect of drugs on homocysteine concentrations. Semin. Vasc. Med. 2005; 5: 124-39. (Pubitemid 40944288)
70. Prodanovich S, Prodanowich S, Ma F, et al,. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J. Am. Acad. Dermatol. 2005; 52: 262-7.
71. Kremer JM,. Toward a better understanding of methotrexate. Arthritis Rheum. 2004; 50: 1370-82. (Pubitemid 38608058)
72. Zonneveld IM, Bakker WK, Dijkstra PF, et al,. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch. Dermatol. 1996; 132: 184-7. (Pubitemid 26058508)
73. Alkins SA, Byrd JC, Morgan SK, et al,. Anaphylactoid reactions to methotrexate. Cancer 1996; 77: 2123-6. (Pubitemid 26142059)
74. Kumar B, Dhar S, Handa S, et al,. Methotrexate in childhood psoriasis. Pediatr. Dermatol. 1994; 11: 271-3. (Pubitemid 24275814)
75. Dadlani C, Orlow SJ,. Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature. J. Am. Acad. Dermatol. 2005; 52: 316-40.
76. Bangert CA, Costner MI,. Methotrexate in dermatology. Dermatol. Ther. 2007; 20: 216-28. (Pubitemid 350029311)
77. Evans WE, Christensen ML,. Drug interactions with methotrexate. J. Rheumatol. Suppl. 1985; 12 (Suppl 12): 15-20. (Pubitemid 16082374)
78. Lester RS,. Methotrexate. Clin. Dermatol. 1989; 7: 128-35.
79. Kalb RE, Strober B, Weinstein G, et al,. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J. Am. Acad. Dermatol. 2009; 60: 824-37.
80. Guidelines for management of patients with psoriasis. Workshop of the Research Unit of the Royal College of Physicians of London; Department of Dermatology, University of Glasgow; British Association of Dermatologists. BMJ 1991; 303: 829-35.
81. Roenigk HH, Auerbach R, Maibach H, et al,. Methotrexate in psoriasis: consensus conference. J. Am. Acad. Dermatol. 1998; 38: 478-85. (Pubitemid 28125534)
82. Weinstein GD,. Methotrexate. Ann. Intern. Med. 1977; 86: 199-204. (Pubitemid 8042802)
83. Boffa MJ, Smith A, Chalmers RJ, et al,. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br. J. Dermatol. 1996; 135: 538-44. (Pubitemid 26341933)
84. Zachariae H, Søgaard H, Heickendorff L,. Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics. Acta Derm. Venereol. 1989; 69: 241-4. (Pubitemid 19110478)
85. Zachariae H, Aslam HM, Bjerring P, et al,. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J. Am. Acad. Dermatol. 1991; 25: 50-3.
86. Mitchell D, Smith A, Rowan B, et al,. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. Br. J. Dermatol. 1990; 122: 1-7. (Pubitemid 20047028)
87. Chalmers RJ, Kirby B, Smith A, et al,. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br. J. Dermatol. 2005; 152: 444-50. (Pubitemid 40547117)
88. Mazurek GH, Villarino ME, CDC,. Guidelines for using the QuantiFERON-TB test for diagnosing latent mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm. Rep. 2003; 52: 15-18.
89. Doll DC, Ringenberg QS, Yarbro JW,. Antineoplastic agents and pregnancy. Semin. Oncol. 1989; 16: 337-46. (Pubitemid 19259007)
90. Menter A, Korman NJ, Elmets CA, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J. Am. Acad. Dermatol. 2009; 61: 451-85.
91. Donnenfeld AE, Pastuszak A, Noah JS, et al,. Methotrexate exposure prior to and during pregnancy. Teratology. 1994; 49: 79-81.
92. Strober BE, Menon K,. Folate supplementation during methotrexate therapy for patients with psoriasis. J. Am. Acad. Dermatol. 2005; 53: 652-9. (Pubitemid 41399934)
93. Kirby B, Lyon CC, Griffiths CE, et al,. The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom. Clin. Exp. Dermatol. 2000; 25: 265-8. (Pubitemid 30670580)
94. Chládek J, Simková M, Vanecková J, et al,. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur. J. Clin. Pharmacol. 2008; 64: 347-55.
95. Salim A, Tan E, Ilchyshyn A, et al,. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br. J. Dermatol. 2006; 154: 1169-74. (Pubitemid 43727401)
96. van Ede AE, Laan RF, Rood MJ, et al,. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001; 44: 1515-24. (Pubitemid 32651731)
97. Lamar LM, Gaethe G,. Pityriasis rubra pilaris. Arch. Dermatol. 1964; 89: 515-22.
98. Dicken CH,. Treatment of classic pityriasis rubra pilaris. J. Am. Acad. Dermatol. 1994; 31: 997-9. (Pubitemid 24365041)
99. Anderson FE,. Pityriasis rubra pilaris treated with methotrexate. Aust. J. Dermatol. 1966; 8: 183-5.
100. Brown J, Perry HO,. Pityriasis rubra pilaris. Treatment with folic acid antagonists. Arch. Dermatol. 1966; 94: 636-8.
101. Parish LC, Woo TH,. Pityriasis rubra pilaris in Korea. Treatment with methotrexate. Dermatologica 1969; 139: 399-403.
102. Knowles WR, Chernosky ME,. Pityriasis rubra pilaris. Prolonged treatment with methotrexate. Arch. Dermatol. 1970; 102: 603-12.
103. Hanke CW, Steck WD,. Childhood-onset pityriasis rubra pilaris treated with methotrexate administered intravenously. Cleve. Clin. Q. 1983; 50: 201-3. (Pubitemid 14233651)
104. Griffiths WA,. Pityriasis rubra pilaris. Clin. Exp. Dermatol. 1980; 5: 105-12. (Pubitemid 10130052)
105. Durairaj VD, Horsley MB,. Resolution of pityriasis rubra pilaris-induced cicatricial ectropion with systemic low-dose methotrexate. Am. J. Ophthalmol. 2007; 143: 709-10. (Pubitemid 46452512)
106. Cornelison RL, Knox JM, Everett MA,. Methotrexate for the treatment of Mucha-Habermann disease. Arch. Dermatol. 1972; 106: 507-8.
107. Lynch PJ, Saied NK,. Methotrexate treatment of pityriasis lichenoides and lymphomatoid papulosis. Cutis 1979; 23: 634-6. (Pubitemid 9167853)
108. Lõpez-Estebaranz JL, Vanaclocha F, Gil R, et al,. Febrile ulceronecrotic Mucha-Habermann disease. J. Am. Acad. Dermatol. 1993; 29: 903-6. (Pubitemid 23335295)
109. Rasmussen JE,. Mucha-Habermann's disease. Arch. Dermatol. 1979; 115: 676-7. (Pubitemid 9249651)
110. Herron MD, Bohnsack JF, Vanderhooft SL,. Septic, CD-30 positive febrile ulceronecrotic pityriasis lichenoides et varioliformis acuta. Pediatr. Dermatol. 2005; 22: 360-5. (Pubitemid 41583320)
111. Perez A, Woods A, Grattan CE,. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br. J. Dermatol. 2010; 162: 191-4.
112. Godse K,. Methotrexate in autoimmune urticaria. Indian J. Dermatol. Venereol. Leprol. 2004; 70: 377. (Pubitemid 40098040)
113. Gach JE, Sabroe RA, Greaves MW, et al,. Methotrexate-responsive chronic idiopathic urticaria: a report of two cases. Br. J. Dermatol. 2001; 145: 340-3. (Pubitemid 32955368)
114. Lyakhovitsky A, Barzilai A, Heyman R, et al,. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J. Eur. Acad. Dermatol. Venereol. 2010; 24: 43-9.
115. Zoller L, Ramon M, Bergman R,. Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema. Isr. Med. Assoc. J. 2008; 10: 413-14.
116. Goujon C, Bérard F, Dahel K, et al,. Methotrexate for the treatment of adult atopic dermatitis. Eur. J. Dermatol. 2006; 16: 155-8.
117. Shaffrali FC, Colver GB, Messenger AG, et al,. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J. Am. Acad. Dermatol. 2003; 48: 417-19. (Pubitemid 36337078)
118. Balasubramaniam P, Ilchyshyn A,. Successful treatment of severe atopic dermatitis with methotrexate. Clin. Exp. Dermatol. 2005; 30: 436-7. (Pubitemid 40835351)
119. Egan CA, Rallis TM, Meadows KP, et al,. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J. Am. Acad. Dermatol. 1999; 40: 612-14. (Pubitemid 29153192)
120. Weatherhead SC, Wahie S, Reynolds NJ, et al,. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br. J. Dermatol. 2007; 156: 346-51. (Pubitemid 46095964)
121. Jablonska S, Chorzelski T, Blaszczyk M,. Immunosuppressants in the treatment of pemphigus. Br. J. Dermatol. 1970; 83: 315-23.
122. Piamphongsant T, Sivayathorn A,. Pemphigus: combined treatment with methotrexate and prednisone. J. Med. Assoc. Thai. 1975; 58: 171-6.
123. Lever WF, Schaumburg-Lever G,. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch. Dermatol. 1977; 113: 1236-41. (Pubitemid 8178525)
124. Lever WF,. Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. Arch. Dermatol. 1972; 106: 491-7.
125. Mashkilleyson N, Mashkilleyson AL,. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm. Venereol. 1988; 68: 413-21.
126. Smith TJ, Bystryn JC,. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch. Dermatol. 1999; 135: 1275-6. (Pubitemid 29493297)
127. Rivitti EA, Camargo ME, Castro RM, et al,. Use of methotrexate to treat pemphigus foliaceus. Int. J. Dermatol. 1973; 12: 119-22.
128. Downham TF, Chapel TA,. Bullous pemphigoid:therapy in patients with and without diabetes mellitus. Arch. Dermatol. 1978; 114: 1639-42. (Pubitemid 9063860)
129. Paul MA, Jorizzo JL, Fleischer AB, et al,. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J. Am. Acad. Dermatol. 1994; 31: 620-5. (Pubitemid 24309781)
130. Dereure O, Bessis D, Guillot B, et al,. Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases. Arch. Dermatol. 2002; 138: 1255-6. (Pubitemid 35025711)
131. Bara C, Maillard H, Briand N, et al,. Methotrexate for bullous pemphigoid: preliminary study. Arch. Dermatol. 2003; 139: 1506-7. (Pubitemid 37433147)
132. Kjellman P, Eriksson H, Berg P,. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch. Dermatol. 2008; 144: 612-16. (Pubitemid 351724421)
133. McCluskey P, Chang JH, Singh R, et al,. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 2004; 111: 796-801. (Pubitemid 38429679)
134. Christen-Zaech S, Hakim MD, Afsar FS, et al,. Pediatric morphea (localized scleroderma): review of 136 patients. J. Am. Acad. Dermatol. 2008; 59: 385-96.
135. Weibel L, Sampaio MC, Visentin MT, et al,. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br. J. Dermatol. 2006; 155: 1013-20. (Pubitemid 44564513)
136. Fitch PG, Rettig P, Burnham JM, et al,. Treatment of pediatric localized scleroderma with methotrexate. J. Rheumatol. 2006; 33: 609-14. (Pubitemid 43334587)
137. Kreuter A, Gambichler T, Breuckmann F, et al,. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch. Dermatol. 2005; 141: 847-52. (Pubitemid 41058065)
138. Uziel Y, Feldman BM, Krafchik BR, et al,. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J. Pediatr. 2000; 136: 91-5. (Pubitemid 30468564)
139. Seyger MM, van den Hoogen FH, de Boo T, et al,. Low-dose methotrexate in the treatment of widespread morphea. J. Am. Acad. Dermatol. 1998; 39: 220-5. (Pubitemid 28367333)
140. Kasteler JS, Callen JP,. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J. Am. Acad. Dermatol. 1997; 36: 67-71. (Pubitemid 27043876)
141. Zieglschmid-Adams ME, Pandya AG, Cohen SB, et al,. Treatment of dermatomyositis with methotrexate. J. Am. Acad. Dermatol. 1995; 32: 754-7.
142. el-Azhary RA, Pakzad SY,. Amyopathic dermatomyositis: retrospective review of 37 cases. J. Am. Acad. Dermatol. 2002; 46: 560-5.
143. Kuhn A, Specker C, Ruzicka T, et al,. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 2002; 46: 600-3.
144. Böhm L, Uerlich M, Bauer R,. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology 1997; 194: 307-8. (Pubitemid 27216055)
145. Wenzel J, Brähler S, Bauer R, et al,. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br. J. Dermatol. 2005; 153: 157-62. (Pubitemid 41044542)
146. Boehm IB, Boehm GA, Bauer R,. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol. Int. 1998; 18: 59-62. (Pubitemid 28432835)
147. Wilson K, Abeles M,. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J. Rheumatol. 1994; 21: 1674-7. (Pubitemid 24285482)
148. Bottomley WW, Goodfield MJ,. Methotrexate for the treatment of discoid lupus erythematosus. Br. J. Dermatol. 1995; 133: 655-6.
149. Goldstein E, Carey W,. Discoid lupus erythematosus: successful treatment with oral methotrexate. Arch. Dermatol. 1994; 130: 938-9. (Pubitemid 24225856)
150. Upchurch KS, Heller K, Bress NM,. Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis. J. Am. Acad. Dermatol. 1987; 17: 355-9. (Pubitemid 17128931)
151. Williams HC, Pembroke AC,. Methotrexate in the treatment of vasculitic cutaneous ulceration in rheumatoid arthritis. J. R. Soc. Med. 1989; 82: 763. (Pubitemid 20016950)
152. Espinoza LR, Espinoza CG, Vasey FB, et al,. Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations. J. Am. Acad. Dermatol. 1986; 15: 508-12. (Pubitemid 16054119)
153. Gansauge S, Breitbart A, Rinaldi N, et al,. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann. Rheum. Dis. 1997; 56: 382-5. (Pubitemid 27305428)
154. Jorizzo JL, White WL, Wise CM, et al,. Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet's disease. J. Am. Acad. Dermatol. 1991; 24: 973-8.
155. Boehm I, Bauer R,. Low-dose methotrexate controls a severe form of polyarteritis nodosa. Arch. Dermatol. 2000; 136: 167-9. (Pubitemid 30090753)
156. Schartz NE, Alaoui S, Vignon-Pennamen MD, et al,. Successful treatment in two cases of steroid-dependent cutaneous polyarteritis nodosa with low-dose methotrexate. Dermatology 2001; 203: 336-8. (Pubitemid 34045199)
157. Quintana G, Matteson EL, Fernández A, et al,. Localized nodular vasculitis: a new variant of localized cutaneous polyarteritis nodosa? Clin. Exp. Rheumatol. 2004; 22: S31-4.
158. Lower EE, Baughman RP,. The use of low dose methotrexate in refractory sarcoidosis. Am. J. Med. Sci. 1990; 299: 153-7. (Pubitemid 20085232)
159. Webster GF, Razsi LK, Sanchez M, et al,. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J. Am. Acad. Dermatol. 1991; 24: 451-4.
160. Veien NK, Brodthagen H,. Cutaneous sarcoidosis treated with methotrexate. Br. J. Dermatol. 1977; 97: 213-16. (Pubitemid 8175916)
161. Lower EE, Baughman RP,. Prolonged use of methotrexate for sarcoidosis. Arch. Intern. Med. 1995; 155: 846-51.
162. Plotner AN, Mutasim DF,. Successful treatment of disseminated granuloma annulare with methotrexate. Br. J. Dermatol. 2010; 163: 1123-4.
163. Lange Wantzin G, Thomsen K,. Methotrexate in lymphomatoid papulosis. Br. J. Dermatol. 1984; 111: 93-5. (Pubitemid 14086232)
164. Vonderheid EC, Sajjadian A, Kadin ME,. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J. Am. Acad. Dermatol. 1996; 34: 470-81. (Pubitemid 26083827)
165. Zackheim HS, Kashani-Sabet M, McMillan A,. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J. Am. Acad. Dermatol. 2003; 49: 873-8. (Pubitemid 37314876)
166. Demierre MF, Vachon L, Ho V, et al,. Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides. Arch. Dermatol. 2003; 139: 624-8. (Pubitemid 36576378)
167. NHMRC. A Guide to the Development, Implementation and Evaluation of Clinical Practice Guidelines. Canberra: National Health and Medical Research Council, Commonwealth of Australia, 1999.
168. Roenigk HH Jr, Auerbach R, Maibach H, et al,. Methotrexate for psoriasis: consensus conference. J. Am. Acad. Dermatol. 1998; 38: 478-85.
169. Black RL, O'Brien WM, Vanscott EJ, et al,. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964; 189: 743-7.
170. Nyfors A, Brodthagen H,. Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica 1970; 140: 345-55.
171. Jeffes EW, Weinstein GD,. Methotrexate and other chemotherapeutic agents used to treat psoriasis. Dermatol. Clin. 1995; 13: 875-90.
172. Zachariae H, Zachariae E,. Methotrexate treatment of psoriatic arthritis. Acta Derm. Venereol. 1987; 67: 270-3. (Pubitemid 17084996)
173. Kragballe K, Zachariae E, Zachariae H,. Methotrexate in psoriatic
174. Nyfors A,. Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics. Dan. Med. Bull. 1978; 25: 208-11. (Pubitemid 9036688)
175. Akhyani M, Chams-Davatchi C, Hemami MR, et al,. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 2010; 24: 1447-51.
176. Flytström I, Stenberg B, Svensson A, et al,. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br. J. Dermatol. 2008; 158: 116-21. (Pubitemid 350221914)
177. Heydendael VM, Spuls PI, Opmeer BC, et al,. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med. 2003; 349: 658-65. (Pubitemid 36975998)
178. Sandhu K, Kaur I, Kumar B, et al,. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J. Dermatol. 2003; 30: 458-63. (Pubitemid 36829974)
179. Ranjan N, Sharma NL, Shanker V, et al,. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study. J. Dermatolog. Treat. 2007; 18: 295-300. (Pubitemid 47537262)
180. Fallah Arani S, Neumann H, Hop WC, et al,. Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. Br. J. Dermatol. 2011; 164: 855-61.
181. Jensen P, Skov L, Zachariae C,. Systemic combination treatment for psoriasis: a review. Acta Derm. Venereol. 2010; 90: 341-9.
182. Gupta R, Gupta S,. Methotrexate-betamethasone weekly oral pulse in psoriasis. J. Dermatolog. Treat. 2007; 18: 291-4. (Pubitemid 47537261)
183. Asawanonda P, Nateetongrungsak Y,. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J. Am. Acad. Dermatol. 2006; 54: 1013-18.
184. Shehzad T, Dar NR, Zakria M,. Efficacy of concomitant use of PUVA and methotrexate in disease clearance time in plaque type psoriasis. J. Pak. Med. Assoc. 2004; 54: 453-5. (Pubitemid 39388207)
185. Zachariae C, Mørk NJ, Reunala T, et al,. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm. Venereol. 2008; 88: 495-501.
186. Fraser AD, van Kuijk AW, Westhovens R, et al,. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann. Rheum. Dis. 2005; 64: 859-64. (Pubitemid 40733909)
187. Mease PJ, Gladman DD, Keystone EC, et al,. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2006; 54: 1638-45.
188. Collins P, Rogers S,. The efficacy of methotrexate in psoriasis-a review of 40 cases. Clin. Exp. Dermatol. 1992; 17: 257-60.
189. Vanderveen EE, Ellis CN, Campbell JP, et al,. Methotrexate and etretinate as concurrent therapies in severe psoriasis. Arch. Dermatol. 1982; 118: 660-2. (Pubitemid 12061439)
190. Rosenbaum MM, Roenigk HH,. Treatment of generalized pustular psoriasis with etretinate (Ro 10-9359) and methotrexate. J. Am. Acad. Dermatol. 1984; 10: 357-61. (Pubitemid 14181965)
191. Horiguchi M, Takigawa M, Imamura S,. Treatment of generalized pustular psoriasis with methotrexate and colchicine. Arch. Dermatol. 1981; 117: 760. (Pubitemid 12248787)
192. Fitzsimons CP, Long J, MacKie RM,. Synergistic carcinogenic potential of methotrexate and PUVA in psoriasis. Lancet 1983; 1: 235-6. (Pubitemid 13171113)
193. Gollnick HP,. Oral retinoids-efficacy and toxicity in psoriasis. Br. J. Dermatol. 1996; 135 (Suppl 49): 6-17.
194. Bonifati C, Carducci M, Mussi A, et al,. Recognition and treatment of psoriasis. Special considerations in elderly patients. Drugs Aging 1998; 12: 177-90. (Pubitemid 28130094)
195. Fairris GM, Dewhurst AG, White JE, et al,. Methotrexate dosage in patients aged over 50 with psoriasis. BMJ 1989; 298: 801-2. (Pubitemid 19084525)
196. Gürcan HM, Ahmed AR,. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br. J. Dermatol. 2009; 161: 723-31.
197. Heilborn JD, StÃ¥hle-Bäckdahl M, Albertioni F, et al,. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J. Am. Acad. Dermatol. 1999; 40: 741-9. (Pubitemid 29230362)
198. Sapadin AN, Fleischmajer R,. Treatment of scleroderma. Arch. Dermatol. 2002; 138: 99-105. (Pubitemid 34056240)
199. Villalba L, Adams EM,. Update on therapy for refractory dermatomyositis and polymyositis. Curr. Opin. Rheumatol. 1996; 8: 544-51. (Pubitemid 27044443)
200. Huber A, Tüting T, Bauer R, et al,. Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. Br. J. Dermatol. 2006; 155: 861-2. (Pubitemid 44352586)
201. Picco P, Gattorno M, Buoncompagni A, et al,. A case of paediatric discoid lupus erythematosus evolving into SLE. Clin. Exp. Rheumatol. 1998; 16: 620. (Pubitemid 28439450)
202. ten Holder SM, Joy MS, Falk RJ,. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann. Pharmacother. 2002; 36: 130-47. (Pubitemid 34055784)
203. Kaye O, Beckers CC, Paquet P, et al,. The frequency of cutaneous vasculitis is not increased in patients with rheumatoid arthritis treated with methotrexate. J. Rheumatol. 1996; 23: 253-7. (Pubitemid 26078380)
204. Badgwell C, Rosen T,. Cutaneous sarcoidosis therapy updated. J. Am. Acad. Dermatol. 2007; 56: 69-83. (Pubitemid 46001778)
205. Prince HM, Whittaker S, Hoppe RT,. How I treat mycosis fungoides and Sézary syndrome. Blood 2009; 114: 4337-53.
206. Wessels JA, Kooloos WM, De Jonge R, et al,. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006; 54: 2830-9. (Pubitemid 44497761)
207. Dervieux T, Wessels JA, van der Straaten T, et al,. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet. Genomics 2009; Epub ahead of print.
208. Kooloos WM, Wessels JA, van der Kooij SM, et al,. Optimalization of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond. Ann. Rheum. Dis. 2009; 68: 1371.